JP7749572B2 - Ｇｌａ遺伝子の突然変異を有する患者におけるファブリー病を治療する方法 - Google Patents

Ｇｌａ遺伝子の突然変異を有する患者におけるファブリー病を治療する方法

Info

Publication number
JP7749572B2
JP7749572B2 JP2022553583A JP2022553583A JP7749572B2 JP 7749572 B2 JP7749572 B2 JP 7749572B2 JP 2022553583 A JP2022553583 A JP 2022553583A JP 2022553583 A JP2022553583 A JP 2022553583A JP 7749572 B2 JP7749572 B2 JP 7749572B2
Authority
JP
Japan
Prior art keywords
mutation
migalastat
seq
patient
gal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022553583A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023516753A (ja
JP2023516753A5 (https=
JPWO2021178737A5 (https=
Inventor
エルフリダ ベンジャミン，
シャオヤン ウー，
Original Assignee
アミカス セラピューティックス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=75267607&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7749572(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アミカス セラピューティックス インコーポレイテッド filed Critical アミカス セラピューティックス インコーポレイテッド
Publication of JP2023516753A publication Critical patent/JP2023516753A/ja
Publication of JP2023516753A5 publication Critical patent/JP2023516753A5/ja
Publication of JPWO2021178737A5 publication Critical patent/JPWO2021178737A5/ja
Priority to JP2025157586A priority Critical patent/JP2026016375A/ja
Application granted granted Critical
Publication of JP7749572B2 publication Critical patent/JP7749572B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2022553583A 2020-03-06 2021-03-05 Ｇｌａ遺伝子の突然変異を有する患者におけるファブリー病を治療する方法 Active JP7749572B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025157586A JP2026016375A (ja) 2020-03-06 2025-09-24 Ｇｌａ遺伝子の突然変異を有する患者におけるファブリー病を治療する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062986297P 2020-03-06 2020-03-06
US62/986,297 2020-03-06
PCT/US2021/020984 WO2021178737A1 (en) 2020-03-06 2021-03-05 Methods of treating fabry disease in patients having a mutation in the gla gene

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025157586A Division JP2026016375A (ja) 2020-03-06 2025-09-24 Ｇｌａ遺伝子の突然変異を有する患者におけるファブリー病を治療する方法

Publications (4)

Publication Number Publication Date
JP2023516753A JP2023516753A (ja) 2023-04-20
JP2023516753A5 JP2023516753A5 (https=) 2024-03-14
JPWO2021178737A5 JPWO2021178737A5 (https=) 2024-03-14
JP7749572B2 true JP7749572B2 (ja) 2025-10-06

Family

ID=75267607

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022553583A Active JP7749572B2 (ja) 2020-03-06 2021-03-05 Ｇｌａ遺伝子の突然変異を有する患者におけるファブリー病を治療する方法
JP2025157586A Pending JP2026016375A (ja) 2020-03-06 2025-09-24 Ｇｌａ遺伝子の突然変異を有する患者におけるファブリー病を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025157586A Pending JP2026016375A (ja) 2020-03-06 2025-09-24 Ｇｌａ遺伝子の突然変異を有する患者におけるファブリー病を治療する方法

Country Status (25)

Country Link
US (1) US20230136297A1 (https=)
EP (2) EP4114390B1 (https=)
JP (2) JP7749572B2 (https=)
KR (1) KR20220152547A (https=)
CN (1) CN115427040A (https=)
AR (1) AR122390A1 (https=)
AU (1) AU2021230371A1 (https=)
BR (1) BR112022017881A2 (https=)
CA (1) CA3170718A1 (https=)
CL (1) CL2022002423A1 (https=)
DK (1) DK4114390T3 (https=)
ES (1) ES3013813T3 (https=)
FI (1) FI4114390T3 (https=)
HR (1) HRP20250179T1 (https=)
HU (1) HUE070116T2 (https=)
IL (1) IL296221A (https=)
LT (1) LT4114390T (https=)
MX (1) MX2022011030A (https=)
PL (1) PL4114390T3 (https=)
PT (1) PT4114390T (https=)
RS (1) RS66530B1 (https=)
SI (1) SI4114390T1 (https=)
SM (1) SMT202500072T1 (https=)
TW (1) TW202146020A (https=)
WO (1) WO2021178737A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4282472A3 (en) * 2018-08-20 2024-02-21 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having a mutation in the gla gene
EP3851105B1 (en) 2019-08-07 2026-03-04 Amicus Therapeutics, Inc. Migalastat for use in treating fabry disease in patients having a mutation in the gla gene

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011514152A (ja) 2008-02-12 2011-05-06 アミカス セラピューティックス インコーポレイテッド 疾病の薬理シャペロン治療に対する応答性を予測する方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
AU2008232614A1 (en) 2007-03-30 2008-10-09 Amicus Therapeutics, Inc. Method for the treatment of Fabry disease using pharmacological chaperones

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011514152A (ja) 2008-02-12 2011-05-06 アミカス セラピューティックス インコーポレイテッド 疾病の薬理シャペロン治療に対する応答性を予測する方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Genetics in medicine，2017年，Vol.19, No.4，pp.430-438
Int. J. Mol. Sci.，2020年01月31日，Vol.21, Article No.956，pp.1-22，doi:10.3390/ijms21030956
Pharmacogenet Genomics.，2008年，Vol.18, No.9，pp.773-780, Author manuscript, pp.1-16

Also Published As

Publication number Publication date
TW202146020A (zh) 2021-12-16
RS66530B1 (sr) 2025-03-31
AR122390A1 (es) 2022-09-07
EP4114390A1 (en) 2023-01-11
EP4114390B1 (en) 2024-12-04
JP2023516753A (ja) 2023-04-20
LT4114390T (lt) 2025-02-10
US20230136297A1 (en) 2023-05-04
WO2021178737A1 (en) 2021-09-10
SMT202500072T1 (it) 2025-03-12
BR112022017881A2 (pt) 2022-12-06
MX2022011030A (es) 2022-12-13
AU2021230371A1 (en) 2022-09-29
KR20220152547A (ko) 2022-11-16
CA3170718A1 (en) 2021-09-10
FI4114390T3 (fi) 2025-03-07
IL296221A (en) 2022-11-01
CL2022002423A1 (es) 2023-05-05
PL4114390T3 (pl) 2025-06-23
PT4114390T (pt) 2025-02-24
CN115427040A (zh) 2022-12-02
EP4527454A2 (en) 2025-03-26
HRP20250179T1 (hr) 2025-04-11
ES3013813T3 (en) 2025-04-15
JP2026016375A (ja) 2026-02-03
EP4527454A3 (en) 2025-09-24
SI4114390T1 (sl) 2025-03-31
HUE070116T2 (hu) 2025-05-28
DK4114390T3 (da) 2025-02-24

Similar Documents

Publication Publication Date Title
US20240277687A1 (en) Methods of treating fabry disease in patients having a mutation in the gla gene
JP7755929B2 (ja) ファブリー病患者における心臓機能の強化及び／または安定化方法
TW201733581A (zh) 在gla基因中具有g9331a突變的患者中治療法布瑞氏症的方法
JP7749572B2 (ja) Ｇｌａ遺伝子の突然変異を有する患者におけるファブリー病を治療する方法
JP7680356B2 (ja) ファブリー病患者の脳血管事象のリスク低減におけるミガロスタットの使用
JP2024525760A (ja) 小児患者のファブリー病を治療する方法
HK40122460A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40104071A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40105450A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40104069A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40104764A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40104441A (en) Methods of treating fabry disease in patients having a mutation in the gla gene
HK40057125A (en) Migalastat for use in methods of treating fabry disease in patients having a mutation in the gla gene
HK40057125B (en) Migalastat for use in methods of treating fabry disease in patients having a mutation in the gla gene
BR112020003974B1 (pt) Métodos para intensificar e/ou estabilizar função cardíaca em pacientes com doença de fabry

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240305

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240305

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250519

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250826

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250924

R150 Certificate of patent or registration of utility model

Ref document number: 7749572

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150